Dexcom (NSDQ:DXCM) this week was ordered to pay attorney’s fees in a spat with rival AgaMatrix over patents related to continuous glucose monitoring technology.

The ruling came alongside a final judgement of non-infringement in favor of AgaMatrix from Judge S. James Otero of the US District Court for the Central District of California Western Division, according to court documents.

Judge Otero also ruled that AgaMatrix’s defenses and counterclaims in response to Dexcom’s first amended complaint for patent infringement were dismissed without prejudice, according to court documents.

DexCom was ordered to pay all taxable costs, including attorney’s fees, according to the documents.

In March, In March, the US Patent Trial and Appeal Board upheld AgaMatrix’s CGM patents in an ongoing spat with Dexcom.